[Atrial fibrillation, oral anticoagulation and nephroprotection: caution or bravery?]

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Atrial fibrillation (AF) and chronic kidney disease (CKD) share risk factors like hypertension and diabetes.
• AF is prevalent in CKD patients, particularly those with end-stage renal disease (ESRD).
• Patients with AF and advanced CKD face higher mortality due to stroke and bleeding risks.

Purpose of the Study:

• To review the application of direct oral anticoagulants (DOACs) in CKD patients.
• To specifically address DOAC therapy in ESRD patients.
• To highlight challenges in anticoagulation for AF patients with kidney disease.

Main Methods:

• Literature review of studies on anticoagulation in CKD and ESRD.
• Analysis of current guidelines and clinical trial data.
• Comparison of DOACs versus vitamin K antagonists (VKAs) in this population.

Main Results:

• DOACs are contraindicated in ESRD.
• VKAs have limitations including narrow therapeutic windows and increased bleeding risk.
• Evidence for DOAC efficacy and safety in non-ESRD CKD patients is evolving.

Conclusions:

• Anticoagulation in AF patients with CKD, especially ESRD, remains a significant clinical challenge.
• Current anticoagulation options (VKAs) have suboptimal risk-benefit profiles.
• Further research is needed to establish safe and effective anticoagulation strategies using DOACs in CKD patients.